ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

ClinicalTrials.gov ID: NCT02304367

Public ClinicalTrials.gov record NCT02304367. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 6:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)-Associated Osteomalacia

Study identification

NCT ID
NCT02304367
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Kyowa Kirin, Inc.
Industry
Enrollment
17 participants

Conditions and interventions

Interventions

  • Burosumab Biological

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 23, 2015
Primary completion
Jul 26, 2017
Completion
Jan 20, 2021
Last update posted
May 5, 2024

2015 – 2021

United States locations

U.S. sites
7
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
Colorado Center for Bone Research at Panorama Orthopedics and Spine Center Golden Colorado 80401
Yale University School of Medicine New Haven Connecticut 06510
Indiana University Hospital Indianapolis Indiana 46202
Johns Hopkins University Baltimore Maryland 21224
Mayo Clinic Rochester Minnesota 55905
Duke University Durham North Carolina 27710
Houston Methodist Research Institute Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02304367, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 5, 2024 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02304367 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →